000 01436 a2200397 4500
005 20250515030116.0
264 0 _c20070123
008 200701s 0 0 eng d
022 _a0143-3334
024 7 _a10.1093/carcin/bgl071
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBos, Carina L
245 0 0 _aProtein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.
_h[electronic resource]
260 _bCarcinogenesis
_cDec 2006
300 _a2371-82 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnti-Inflammatory Agents, Non-Steroidal
_xpharmacology
650 0 4 _aCell Line, Tumor
650 0 4 _aColitis, Ulcerative
_xdrug therapy
650 0 4 _aColonic Neoplasms
650 0 4 _aColorectal Neoplasms
_xprevention & control
650 0 4 _aHumans
650 0 4 _aKinetics
650 0 4 _aMesalamine
_xpharmacology
650 0 4 _aPhosphoprotein Phosphatases
_xmetabolism
650 0 4 _aProtein Phosphatase 2
650 0 4 _aWnt Proteins
_xantagonists & inhibitors
650 0 4 _abeta Catenin
_xantagonists & inhibitors
700 1 _aDiks, Sander H
700 1 _aHardwick, James C H
700 1 _aWalburg, Kimberley V
700 1 _aPeppelenbosch, Maikel P
700 1 _aRichel, Dick J
773 0 _tCarcinogenesis
_gvol. 27
_gno. 12
_gp. 2371-82
856 4 0 _uhttps://doi.org/10.1093/carcin/bgl071
_zAvailable from publisher's website
999 _c16325920
_d16325920